We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of Liraglutide on Cardiovascular Function and Myocardial Tissue Characteristics in Type 2 Diabetes Patients of South Asian Descent Living in the Netherlands: A Double-Blind, Randomized, Placebo-Controlled Trial.
- Authors
Paiman, Elisabeth H.M.; Eyk, Huub J.; Aalst, Minke M.A.; Bizino, Maurice B.; Geest, Rob J.; Westenberg, Jos J.M.; Geelhoed‐Duijvestijn, Petronella H.; Kharagjitsingh, Aan V.; Rensen, Patrick C.N.; Smit, Johannes W.A.; Jazet, Ingrid M.; Lamb, Hildo J.; van Eyk, Huub J; van Aalst, Minke M A; van der Geest, Rob J; Geelhoed-Duijvestijn, Petronella H
- Abstract
<bold>Background: </bold>The glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide may be beneficial in the regression of diabetic cardiomyopathy. South Asian ethnic groups in particular are at risk of developing type 2 diabetes.<bold>Purpose: </bold>To assess the effects of liraglutide on left ventricular (LV) diastolic and systolic function in South Asian type 2 diabetes patients.<bold>Study Type: </bold>Prospective, double-blind, randomized, placebo-controlled trial.<bold>Population: </bold>Forty-seven type 2 diabetes patients of South Asian ancestry living in the Netherlands, with or without ischemic heart disease, who were randomly assigned to 26-week treatment with liraglutide (1.8 mg/day) or placebo.<bold>Field Strength/sequence: </bold>3T (balanced steady-state free precession cine MRI, 2D and 4D velocity-encoded MRI, 1 H-MRS, T1 mapping).<bold>Assessment: </bold>Primary endpoints were changes in LV diastolic function (early deceleration peak [Edec], ratio of early and late peak filling rate [E/A], estimated LV filling pressure [E/Ea]) and LV systolic function (ejection fraction). Secondary endpoints were changes in aortic stiffness (aortic pulse wave velocity [PWV]), myocardial steatosis (myocardial triglyceride content), and diffuse fibrosis (extracellular volume [ECV]).<bold>Statistical Tests: </bold>Data were analyzed according to intention-to-treat. Between-group differences were reported as mean (95% confidence interval [CI]) and were assessed using analysis of covariance (ANCOVA).<bold>Results: </bold>Liraglutide (n = 22) compared with placebo (n = 25) did not change Edec (+0.2 mL/s2 × 10-3 (-0.3;0.6)), E/A (-0.09 (-0.23;0.05)), E/Ea (+0.1 (-1.2;1.3)) and ejection fraction (0% (-3;2)), but decreased stroke volume (-9 mL (-14;-5)) and increased heart rate (+10 bpm (4;15)). Aortic PWV (+0.5 m/s (-0.6;1.6)), myocardial triglyceride content (+0.21% (-0.09;0.51)), and ECV (-0.2% (-1.4;1.0)) were unaltered.<bold>Data Conclusion: </bold>Liraglutide did not affect LV diastolic and systolic function, aortic stiffness, myocardial triglyceride content, or extracellular volume in Dutch South Asian type 2 diabetes patients with or without coronary artery disease.<bold>Level Of Evidence: </bold>1 Technical Efficacy Stage: 4 J. Magn. Reson. Imaging 2020;51:1679-1688.
- Subjects
NETHERLANDS; SOUTH Asians; TYPE 2 diabetes; PEOPLE with diabetes; DOPPLER echocardiography; CORONARY disease; VENTRICULAR ejection fraction; DIABETIC cardiomyopathy; RESEARCH; RESEARCH methodology; MEDICAL cooperation; EVALUATION research; COMPARATIVE studies; RANDOMIZED controlled trials; BLIND experiment; RESEARCH funding; STATISTICAL sampling; LONGITUDINAL method; CARDIOVASCULAR disease diagnosis
- Publication
Journal of Magnetic Resonance Imaging, 2020, Vol 51, Issue 6, p1679
- ISSN
1053-1807
- Publication type
journal article
- DOI
10.1002/jmri.27009